Aquestive Therapeutics (AQST) Research & Development (2017 - 2025)
Historic Research & Development for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to $4.5 million.
- Aquestive Therapeutics' Research & Development fell 1402.54% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.9 million, marking a year-over-year increase of 362.72%. This contributed to the annual value of $20.3 million for FY2024, which is 5476.19% up from last year.
- Per Aquestive Therapeutics' latest filing, its Research & Development stood at $4.5 million for Q3 2025, which was down 1402.54% from $4.1 million recorded in Q2 2025.
- Over the past 5 years, Aquestive Therapeutics' Research & Development peaked at $5.9 million during Q1 2024, and registered a low of $2.9 million during Q4 2023.
- Its 5-year average for Research & Development is $4.3 million, with a median of $4.3 million in 2022.
- Its Research & Development has fluctuated over the past 5 years, first plummeted by 3490.36% in 2021, then soared by 7025.62% in 2024.
- Aquestive Therapeutics' Research & Development (Quarter) stood at $4.4 million in 2021, then fell by 2.77% to $4.3 million in 2022, then tumbled by 32.49% to $2.9 million in 2023, then soared by 70.26% to $4.9 million in 2024, then fell by 7.87% to $4.5 million in 2025.
- Its last three reported values are $4.5 million in Q3 2025, $4.1 million for Q2 2025, and $5.4 million during Q1 2025.